- Conditions
- Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
- Interventions
- Telephone reminder, Text Message reminder
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 749 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 470
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Papilloma Virus (HPV)
- Interventions
- Text Message, PostCard, Standard of Care, Motivational Interview
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1006
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more
- Conditions
- Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma, Laryngeal Papilloma, Recurrent, Respiratory Papillomatosis, Human Papilloma Virus
- Interventions
- Avelumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Papillomavirus Infections
- Interventions
- human papillomavirus vaccine L1, type 6,11,16,18
- Biological
- Lead sponsor
- Eisenhower Army Medical Center
- Federal
- Eligibility
- 18 Years to 26 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Fort Gordon, Georgia
- Conditions
- Human Papillomavirus
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 100 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2047
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Human Papillomavirus (HPV)-Related Malignancies, Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
- Interventions
- Ribavirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Cervical Carcinoma, Human Papillomavirus Infection
- Interventions
- HPV Self-Collection, Interview, Survey Administration
- Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
- Conditions
- HPV, Throat Cancer, Oropharyngeal Carcinoma, Oropharyngeal Cancer, Human Papilloma Virus
- Interventions
- 18 F-FMISO PET/CT, Radiation, Cisplatin, Carboplatin, 5-fluorouracil
- Diagnostic Test · Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Oropharynx Cancer
- Interventions
- MRIdian Linac
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Human Papillomavirus, CIN 2, CIN 3
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 13 Years to 22 Years · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1987 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • San Leandro, California
- Conditions
- Human Papillomavirus
- Interventions
- Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
- Diagnostic Test
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections, Sexually Transmitted Diseases
- Interventions
- Quadrivalent HPV vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years to 45 Years · Female only
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more
- Conditions
- Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
- Interventions
- placebo, A007
- Drug
- Lead sponsor
- Tigris Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
- Conditions
- HPV-Related Oropharynx Squamous Cell Carcinoma
- Interventions
- Radiation therapy, Cisplatin, Surgery
- Radiation · Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Fargo, North Dakota • Sioux Falls, South Dakota
- Conditions
- Anal Cancer
- Interventions
- Self-sampling, Nylon-flocked Swab
- Behavioral · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Houston, Texas • Milwaukee, Wisconsin
- Conditions
- Human Papillomavirus (HPV) Vaccines
- Interventions
- Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,296 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- GATA2 Deficiency
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Papillomavirus Infections
- Interventions
- 851B
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 22
- States / cities
- Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
- Conditions
- Human Papilloma Virus (HPV)
- Interventions
- cobas® 4800 HPV Test
- Device
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 47,208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 61
- States / cities
- Enterprise, Alabama • Hoover, Alabama • Mobile, Alabama + 54 more
- Conditions
- Aerodigestive Precancerous Lesions and Malignancies
- Interventions
- INO-3106, INO-9012
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HPV-Associated Cancers
- Interventions
- Ad-E6E7, MG1-E6E7, Atezolizumab
- Biological
- Lead sponsor
- Turnstone Biologics, Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Miami, Florida • Billings, Montana • New York, New York + 2 more
- Conditions
- Sexual Transmission of Infection
- Interventions
- Gardasil Vaccine, Placebo
- Biological · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 16 Years to 24 Years · Female only
- Enrollment
- 406 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida